These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38186008)

  • 1. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
    Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
    J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
    Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
    Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
    Gultekin M; Guler OC; Yuce Sari S; Akkus Yildirim B; Onal C; Celik H; Yuce K; Ayhan A; Arik Z; Kose F; Altundag O; Zoto Mustafayev T; Atalar B; Bolukbasi Y; Yildiz F
    J Obstet Gynaecol; 2021 Apr; 41(3):414-420. PubMed ID: 32347768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas.
    Njølstad TS; Engerud H; Werner HM; Salvesen HB; Trovik J
    Gynecol Oncol; 2013 Nov; 131(2):410-5. PubMed ID: 24004646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological outcomes of minimally invasive surgery in non-endometrioid endometrial Cancer patients with varying prognostic risks: a retrospective cohort study based on the ESGO/ESTRO/ESP 2020 guidelines.
    Liu B; Liu Y; Liu W; Lin C; Lin L; Chen W; Lin W; Chen W; Lin J
    BMC Surg; 2024 Sep; 24(1):254. PubMed ID: 39256669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
    Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
    J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population.
    Ortoft G; Høgdall C; Hansen ES; Dueholm M
    Int J Gynecol Cancer; 2021 Aug; 31(8):1116-1124. PubMed ID: 34112735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
    Nero C; Pasciuto T; Cappuccio S; Corrado G; Pelligra S; Zannoni GF; Santoro A; Piermattei A; Minucci A; Lorusso D; Fanfani F; Scambia G
    Cancer; 2022 Aug; 128(15):2898-2907. PubMed ID: 35617463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
    Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
    Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
    Bendifallah S; Ouldamer L; Lavoue V; Canlorbe G; Raimond E; Coutant C; Graesslin O; Touboul C; Collinet P; Daraï E; Ballester M;
    Gynecol Oncol; 2017 Jan; 144(1):107-112. PubMed ID: 27789083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution.
    Kumar UP; Yathiraj PH; Sharan KT; Kamath A; Singh A; Reddy SA; Alurkar P; Fernandes DJ; Mamidipudi VS
    Int J Gynecol Cancer; 2018 Jun; 28(5):854-860. PubMed ID: 29683879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study.
    Zhang Y; Chu R; Zhang Z; Xu C; Liu J; Zhang J; Wang J; Wang Q; Liu C; Feng J; Yao Q; Yao S; Xue F; Guo H; Xia M; Wang X; Zhao W; Li X; Lin B; Zhao X; Ma J; Zhang P; Guo R; Gao Q; Sun C; Ma D; Kong B; Li Y; Chen G; Song K;
    Gynecol Oncol; 2023 Sep; 176():43-52. PubMed ID: 37442025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population.
    Gorelick C; Andikyan V; Mack M; Lee YC; Abulafia O
    Int J Gynecol Cancer; 2009 Nov; 19(8):1384-9. PubMed ID: 20009894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial Cancer: Analysing Patterns of Recurrence and Real-Life Outcome Data Using the 2020 ESGO-ESTRO-ESP Risk Stratification System.
    Karkia R; Nyakunengwa TR; Uwins C; Stewart A; Patel H; Tailor A; Ellis P; Butler-Manuel S; Chatterjee J
    Clin Oncol (R Coll Radiol); 2024 Nov; 36(11):719-727. PubMed ID: 38942617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors.
    Todenhöfer T; Renninger M; Schwentner C; Stenzl A; Gakis G
    BJU Int; 2012 Dec; 110(11 Pt B):E533-40. PubMed ID: 22578156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer.
    Holub K; Biete A
    BMC Cancer; 2018 Dec; 18(1):1280. PubMed ID: 30577833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant radiotherapy for stage I endometrial cancer.
    Kong A; Johnson N; Kitchener HC; Lawrie TA
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003916. PubMed ID: 22513918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent patterns after postoperative radiotherapy for early stage endometrial cancer: A competing risk analysis model.
    Ren K; Wang W; Sun S; Hou X; Hu K; Zhang F
    Cancer Med; 2022 Jan; 11(1):257-267. PubMed ID: 34779587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.